Skip to content
value.today

Cell Source, Inc. and its peers

2 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.

Companies in the group

Up to 12. Remove or re-base from the table's column heads.

Also: these companies in the compare tool.

Keep this group

Save it for yourself or, in a team, for everyone in it.

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Zivo Bioscience Inc.ZIVO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Karyopharm Therapeutics Inc.KPTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $146 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Seres Therapeutics, Inc.MCRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Black Hawk Acquisition CorporationBKHA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Aytu BioscienceAYTU · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (Oct 26, 2026) · revenue $58 M (year to June 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Reviva Pharmaceuticals Holdings, Inc.RVPH · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (last known, Mar 8, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Sigyn Therapeutics, Inc.SIGY · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (last known, Jan 7, 2022)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Cocrystal Pharma, Inc.COCP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Senti Biosciences, Inc.SNTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • BeyondSpring Inc.BYSI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Context Therapeutics Inc.CNTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 27, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Lipocine Inc.LPCN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $18 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $18 M (Oct 13, 2026) · revenue $2 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Cell Source, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Cell Source, Inc., BeyondSpring Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCell Source, Inc.base
CLCS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
BeyondSpring Inc.
BYSI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$20 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one2nd of 2$22 MOct 30, 2026 · Market data1st of 2$21 M2 ranked
Net income (Higher is better)$-5 MFY2024 · SEC2nd of 2$-1 MFY2025 · SEC1st of 2$-3 M2 ranked
Valuation
Free cash flow yield (Higher is better)————-92.1%price Oct 30, 2026 · Market dataonly one with it9th3rd-92.1%—
Scorecard
Scorecard (Higher is better)0 of 6FY2024 · Scorecard2nd of 22 of 9FY2025 · Scorecard1st of 211% passed2 ranked
Valuation checks (Higher is better)——0 of 4FY2025 · Scorecardonly one with it0% passed—
Growth checks (Higher is better)0 of 2FY2024 · Scorecard2nd of 21 of 1FY2025 · Scorecard1st of 250% passed2 ranked
Profitability checks (Higher is better)0 of 2FY2024 · Scorecard1st of 20 of 2FY2025 · Scorecard1st of 20% passed2 ranked
Financial health checks (Higher is better)0 of 1FY2024 · Scorecard2nd of 21 of 2FY2025 · Scorecard1st of 225% passed2 ranked
Shareholder returns checks (Higher is better)0 of 1FY2024 · Scorecardonly one with it——0% passed—
Ownership
Held by institutions (Better neither way: ranked highest first)——13.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it13.1%—
Institutions holding (Better neither way: ranked highest first)——192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it19—
Institutional holding, change over the quarter (Better neither way: ranked highest first)——+0.2 pp2026-Q2 against 2026-Q1 · 13Fonly one with it+0.2 pp—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cell Source, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BeyondSpring Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Free cash flow yield#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Free cash flow yield: each company's figure and its percentile in its sector and its country
CompanyFree cash flow yieldIn its sectorIn its country
Cell Source, Inc.———
BeyondSpring Inc.-92.1%fiscal 2025
9th percentile in Healthcaremedian -6.3%, 675 companies
3rd percentile in USAmedian 2.5%, 2,914 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$0 M$1 M$1 M$1 M2022BeyondSpring Inc. $1 M

Rank in the group

Ranks need two fiscal years with the figure for at least two of these companies.

Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCell Source, Inc.BeyondSpring Inc.
2022—$1 MSEC
2021—$1 MSEC

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.